References
- Bostwick JM. 2012. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 87:172–186.
- Di Marzo V. 1999. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci. 65:645–655.
- Di Marzo V, Petrocellis LD. 2006. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med. 57:553–574.
- Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. 2014. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci. 97:45–54.
- Fernandez-Ruiz J, Moro MA, Martinez-Orgado J. 2015. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics. 12:793–806.
- Friedman D, Devinsky O. 2015. Cannabinoids in the treatment of epilepsy. N Engl J Med. 373:1048–1058.
- Guzman M. 2003. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 3:745–755.
- Hanus LO, Meyer SM, Munoz E, Taglialatela-Scafati O, Appendino G. 2016. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 33(12):1357–1392.
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Physiol Rev. 54:161–202.
- Kano M, Ohno-Shosaku T, Maejima T. 2002. Retrograde signaling at central synapses via endogenous cannabinoids. Mol Psychiatry. 7:234–235.
- Lynch ME, Ware MA. 2015. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 10:293–301.
- Martin BR, Mechoulam R, Razdan RK. 1999. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:573–595.
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:561–564.
- Parker LA, Rock EM, Limebeer CL. 2011. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 163:1411–1422.
- Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. 2005. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 434:782–786.
- Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. 1993. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem. 61:352–355.
- Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N. 2003. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 23:1398–1405.